Articles tagged with Prostate Cancer
Researchers found that high dose radiotherapy (74 Gy) improved cancer control and reduced the need for additional hormone treatment compared to standard radiotherapy (64 Gy). The new conformal radiotherapy method minimized bowel side effects.
The study demonstrates that real-time intra-operative planning consistently achieves optimal coverage of the prostate with minimal doses to healthy structures. This results in improved survival rates and reduced side effects, saving $450 million a year nationwide.
A UCLA study found that three common prostate cancer treatments affect men's lives in different ways, with varying degrees of erectile dysfunction and urinary symptoms. The study tracked 580 men for five years and used a web-based data collection system to gather accurate information.
Researchers found that the androgen receptor plays a key role in bladder cancer development, which explains why it affects men more than women. The discovery opens doors to new treatment options and may help doctors predict tumor recurrence.
The American Association for Cancer Research (AACR) has awarded its inaugural Team Science Award to a multidisciplinary team of researchers from the University of Michigan and Harvard Medical School/Brigham and Women's Hospital. The award recognizes their groundbreaking discovery of gene fusions in prostate cancer, which has significan...
Men with lower educational levels experience a significant drop in quality of life after prostate cancer treatment compared to those with more education. The study controlled for various factors, including income and healthcare access, to show that low education alone is associated with lower quality of life.
A study of 372 men with prostate cancer found that 49% had osteoporosis, with those receiving hormone therapy and having undergone radical prostatectomy being at highest risk. The authors suggest that daily calcium intake could be used as a prognostic factor for osteoporosis in these patients.
Scientists from Wake Forest University School of Medicine found that stress hormone epinephrine can cause changes in prostate and breast cancer cells, making them resistant to cell death. This link between stress and cancer has been suggested but previously unexplored, with potential implications for patients and researchers.
Researchers are investigating a genetically modified variant of Avian Newcastle disease virus to treat human prostate cancer. The virus is designed to replicate only in the presence of prostate-specific antigen, found exclusively in cancerous cells.
A detectable PSA level is first indicator of recurrent prostate cancer after radical prostatectomy, with a doubling time of less than three months indicating imminent death from prostate cancer. Patients with longer doubling times are at significant risk for disease recurrence and cancer-specific death.
New study finds that PSA measurement is associated with prostate cancer prognosis but poorly predicts lethal cancer. Researchers emphasize the need for improved surveillance strategies to identify life-threatening tumors.
A study led by USC and Harvard researchers identified multiple genetic risk factors that predict a man's probability of developing prostate cancer. The findings highlight the importance of this region in prostate cancer, providing potential tools for early screening and prevention efforts.
Researchers, Lucille Sanzero Eller and Elise Lev, are developing a targeted intervention to address physical and psychological symptoms in men with prostate cancer. The study aims to improve quality of life by reducing symptoms such as urinary and bowel incontinence and depression.
A study by Duke University Medical Center researchers found that obese and overweight men are more likely to have aggressive prostate cancer than biopsy results indicate. This discrepancy may lead to inadequate or inappropriate treatment, emphasizing the need for more accurate biopsies.
Alan Garen and Zhiwei Hu have developed a way to target and destroy tumor blood vessels using nanoparticles. The technology uses a synthetic gene that activates an immune response, allowing for selective destruction of tumors while leaving normal tissue unharmed.
A study found that patients who received preventive health exams were more likely to undergo cancer screenings, including colorectal, breast, and prostate cancer testing. The examination may serve as a forum for promoting evidence-based cancer screening.
Cancer researchers have identified a promising compound, ASC-J9, that slows the progression of Kennedy's disease in mice carrying the mutant human gene. The compound breaks up a molecular clog in neurons affected by the disease, improving mobility and muscle function.
A study by Haojie Li and colleagues found that vitamin D deficiency is common among US men, affecting prostate cancer risk. Genetic variations in the VDR gene are also associated with an increased risk of developing prostate cancer.
Research at UCSD School of Medicine suggests inflammation associated with tumor growth plays a key role in prostate cancer metastasis. A signaling pathway triggered by RANK ligand increases metastases in mouse models.
Men diagnosed with obese prostate cancer have a 2.6-fold greater risk of dying compared to normal-weight men with the same profile, regardless of treatment or disease stage. Obesity also significantly increases risk of cancer spreading into distant organs, according to researchers at Fred Hutchinson Cancer Center.
African-American men face significant barriers to timely diagnosis and screening due to constrained healthcare access, distrust of physicians, and socioeconomic disadvantages. The study reveals that knowledge about prostate cancer is comparable to that of white men, but lack of trust in medical care leads to irregular interactions and ...
A study from UNC School of Medicine suggests that improving healthcare access is key to reducing disparities in prostate cancer among black men. The lack of regular healthcare and trust in physicians hindered their ability to receive preventative care, leading to higher death rates.
Dr. John A. Martignetti received a $6.1 million grant to investigate the potential therapeutic role of siRNA in metastatic prostate cancer. The award aims to improve survival and reduce side effects and death for men with advanced prostate cancer.
Researchers at the University of Virginia Health System are investigating molecular therapies for prostate cancer. They plan to identify compensatory pathways and develop combination therapies using a laboratory-made screening approach.
Researchers found that changes in breast density over time can predict a woman's risk of breast cancer, with higher densities linked to greater risks. Meanwhile, targeting prostate-specific proteins may lead to effective treatments for prostate cancer and other diseases, leaving non-prostate cells unharmed.
Men who receive false-positive prostate cancer results experience heightened anxiety about their risk of developing the disease and report issues with sexual function. The study emphasizes the importance of discussing the pros and cons of screening with patients to minimize adverse effects on quality of life.
Researchers found that a combination of green tea polyphenol EGCG and COX-2 inhibitor celecoxib can slow the growth of human prostate cancer. The study demonstrated a synergistic effect, where both agents triggered cellular pathways that were more powerful when combined.
A new study found that androgen deprivation therapy for prostate cancer may increase the risk of death from heart disease in patients over age 65. After adjusting for other cardiovascular risk factors, researchers found a significant link between ADT use and cardiac-related deaths among older men.
A VA researcher has developed a method to identify men at risk for high-grade prostate cancer, reducing the need for unnecessary biopsies. The study found that a high PSA adjusted for prostate size and Gleason scores above 7 indicate a higher risk of life-threatening prostate cancer.
A new class of targeted cancer drugs, pertuzumab, shows promise in slowing the progression of recurrent prostate cancer. The study found that prolonged median survival time was achieved by 16.4 months with the drug compared to 10.7 months in a historical control group.
Scientists have identified a severe form of benign prostatic hyperplasia (BPH) tied to a gene called JM-27. A blood test detects high levels of this protein, indicating more severe symptoms. This discovery could lead to earlier diagnosis and targeted treatment for bladder-related complications.
A University of Illinois study reveals that combining tomatoes and broccoli in the diet can effectively reduce prostate tumors. The study found that eating both foods together produces an additive effect, with tumor cells proliferating more slowly.
A new study has found that excess weight and adult weight gain increase the risk of death from prostate cancer. Higher BMI and weight gain since age 18 were associated with a significantly higher risk of fatal outcomes.
A recent study published in the Journal of the National Cancer Institute found that men with only daughters had a higher risk of prostate cancer than those with at least one son. The research suggests that genes on the Y chromosome may be involved in prostate cancer risk, and that lack of sons increases this risk by 40%.
Researchers have developed a promising radiotracer, FACBC, to improve prostate cancer diagnosis and staging. The tracer shows high accumulation in cancer cells and potential for overcoming traditional PET tracers' drawbacks.
A study found that prostate cancer treatment costs are substantial and sustained, with cumulative costs averaging $42,570 over five years. The cost of treatments varies by type, age, and disease risk, with watchful waiting being the least expensive option.
An observational study found that elderly men who received treatment for localized prostate cancer survived significantly longer than those who did not. The study suggested a reduced risk of mortality associated with active treatment in the elderly Medicare population.
A study of SEER-Medicare records found that surgery or radiation therapy for early-stage prostate cancer increased lifespan in men between 65 and 80 years old. Treatment was associated with a 30% lower risk of death compared to observation, even for elderly men with low-risk disease.
Researchers found that older men diagnosed with localized prostate cancer who received treatment lived significantly longer than those who didn't receive treatment. After accounting for differences, the study discovered a 31% lower risk of death in patients who underwent surgery or radiation therapy.
A multicenter study found that finasteride artificially lowers PSA levels in younger men taking it for hair growth, impacting diagnosis accuracy. The study calls for new clinical guidelines to account for this effect when evaluating PSA results.
Research from the Flint Men's Health Study found that African-American men with prostate cancer were more likely to report a family history of both diseases among siblings. This increased risk was particularly notable for having a brother diagnosed with prostate cancer and a sister diagnosed with breast cancer, highlighting the importa...
Researchers found that a radical prostatectomy can be a viable option for select octogenarian patients with localized prostate cancer. The 10-year survival rate was similar to that observed in healthy patients 60-79 years old undergoing a radical prostatectomy.
Thomas Jefferson University researchers have found a connection between an aging gene and the prevention of prostate cancer cell growth. The study reveals that SIRT1, a sirtuin enzyme, can block cancer growth by inhibiting the activity of mutated androgen receptors, which are resistant to current therapies.
A survey of over 700 family doctors found that nearly two-thirds provide PSA tests on request, despite lack of evidence supporting its effectiveness. The study highlights the need for better training and targeted guidance to influence testing patterns and improve patient outcomes.
A study found that testosterone replacement therapy had little effect on prostate tissue, contrary to previous concerns. The treatment increased serum testosterone levels but showed no significant changes in prostate histology or cancer incidence.
A study found that adding radiation therapy after prostate gland removal reduced PSA relapse and disease recurrence risk by 50% and 38%, respectively. However, it did not improve overall survival or metastasis-free survival.
A study of nearly 600,000 men aged 70 and older reveals that 56 percent had a routine PSA screening, despite lack of recommendation. Health status had little impact on whether a test was performed, with even those in poor health receiving the test.
Scientists at the American Association for Cancer Research have developed a novel method to detect DNA methylation in exhaled breath, which may help predict lung cancer development. The test has also shown promise in identifying patients with pancreatic cancer, raising hopes for early detection and treatment.
Scientists have developed a protoxin that targets and kills prostate cancer cells using the protein PSA made by prostate cancer. The therapy shows promise in treating locally recurrent or advanced prostate cancer, with potential to reduce enlarged prostate size. A phase I clinical trial is currently underway.
A large-scale study involving over 7,500 men with prostate cancer has concluded that a rise in PSA levels after treatment, known as PSA bounce, does not impact overall survival. The study found no statistical difference in survival rates between patients who experienced a bounce and those who did not.
A new study suggests that a rapidly rising PSA level before treatment is a key indicator of cancer spread in men with clinically localized prostate cancer. The study found that men with a high PSA velocity (PSAV) are at greater risk of metastatic disease and should receive hormone therapy in addition to radiation.
Researchers have discovered a biochemical pathway by which the sex hormone androgen increases levels of reactive oxygen species in the prostate gland, contributing to prostate cancer development. A new drug, MDL 72,527, has been shown to block this pathway, significantly prolonging survival and inhibiting tumour growth in mice.
Researchers at Johns Hopkins Kimmel Cancer Center found overproduction of myosin VI in prostate tumor cells and precancerous lesions. Silencing myosin VI in lab studies reduced cell invasion, suggesting its critical role in starting and maintaining malignant properties of most human prostate cancers.
Researchers found a correlation between high COX-2 intensity scores and increased risk of biochemical failure and distant metastasis. The study suggests that inhibiting COX-2 expression may make prostate cancer more responsive to radiation therapy.
A large study of over 7,500 men with prostate cancer treated with radiation therapy found that temporary PSA bounces do not increase the risk of cancer recurrence. Researchers believe this reduces stress and uncertainty for patients experiencing a PSA bounce after radiation.
A new classification system, called the Phoenix definition, provides a better evaluation method for predicting patient outcomes in recurrent prostate cancer. The study demonstrates significant improvement in predicting endpoints such as distant metastasis and overall mortality.
Patients treated with IMRT had significantly fewer moderate and serious side effects, including urethral stricture and catheterization, compared to those who received I-125 seed brachytherapy. The study found excellent PSA outcomes after treatment in both groups.
Researchers found that higher doses of 74-82 Gray radiation significantly reduce the risk of prostate cancer spreading to other parts of the body, even 8-10 years after treatment. Treatment centers using IMRT or 3D conformal radiation therapy with high doses can prevent cancer spread.
A study found that patients base their treatment choice on cultural and personal prejudices, with false beliefs about radiation's impact being a major concern. Patients were also anxious about the terminology used in radiation therapy, evoking feelings more related to war than a cure.
A study found that longer-term hormone therapy does not extend survival for high-risk prostate cancer patients. Instead, it may lead to a lesser degree of treatment side effects and improved quality of life.